Sickle Cell DiseasePipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030

Sickle-cell diseases (SCD) are types of blood disorders which are usually inherited genetically. One of the common types of SCDs is the sickle-cell anemia or SCA. It essentially gives rise to an irregularity in hemoglobin, the protein that carries oxygen in the blood. Hemoglobin is found typically in the red blood cells of the body. As a result, a sickle-like shaped cell is formed under certain conditions. Tribulations in sickle cell disease usually start to take shape at a very early age (within the first year of birth). This might lead to various health problems including pain attacks also known as the sickle-cell crisis, swelling in the limbs, microbial infections, and in certain cases, stroke. SCD is diagnosed by blood tests and Hb electrophoresis. Hydroxyurea is the only FDA approved drug for treatment of Sickle-cell diseases.

 Key Developments:

• In December 2017, Novartis Pharmaceuticals released results of post hoc subgroup analysis of the Phase II SUSTAIN study of crizanlizumaban investigational humanized anti-P-selectin monoclonal antibody determined that crizanlizumab delayed the time to first sickle cell pain crisis in patients vs. placebo in key subgroups of adult patients with sickle cell disease
• In February 2017, bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease.